



IWGDF Guidelines – Disclosure of interest form

Name: Stephanie Wu

Affiliation: Dr. William M. Scholl College of Podiatric
Medicine at Rosalind Franklin University

Position: Dean and Professor

IWGDF Working Group: Wound Healing

For the following items, please disclose any interest from the past five years that might be perceived by others as potentially influencing your judgment in any topic in the IWGDF Guideline(s) that you contribute to.

- Ancillary positions: none

- Personal financial interests: none

Do you have personal financial interests such as stocks and shares? If yes, please declare: No

Do you have personally received finances, funding for an account that you benefit from financially or professionally, for honorary fees or consultancy? If yes, please declare:

TissueTech, Inc. – consultancy fee

Medaxis Ag – consultant for research study (starting in July, 2021)

E02 Concepts Inc. – consultancy fee

- Personal relations (this includes personal relations or relations via close family that might be perceived by others as potentially influencing your judgment): None

- Externally funded research (this includes research funding awarded to you as project member, or to your department, for funding that might be perceived by others as potentially influencing your judgment). If yes, name the title/topic of the grant.

1. Principal Investigator, “Summer Research Fellowship Program for Podiatric Medical Students” NIH T35 Grant. Award Number: 2T35DK074390-11, \$288,000, 05/01/2020 – 04/30/2024

2. Co-Investigator, “Improving Diabetic Foot Ulcer Offloading: A Pilot Study on the Impact of Removable Cast Walker Design Factors on Usability” NIH R01 Grant. Award Number: 1R01DK131303-01A1, \$779,890.00, 08/01/2022 – 05/31/2025

3. Principal Investigator, “A Phase II Double-Blind, Randomized, Placebo Controlled Study to Assess the Efficacy and Safety of AMG0001 To Improve Ulcer Healing and Perfusion in Subjects Who Have Peripheral Ischemic Ulcers of the Lower.” Total budget amount:

\$165,100 (\$132,080 direct costs and indirect costs \$33,020). Overall Budget Period is: 4/15/20 - 4/14/23

4. Principal Investigator, “A Registry Study for Subjects who Participated in AMBULATE DFU and AMBULATE DFU II.” Total budget amount: \$13,187.50 (\$10,550.00 direct costs and indirect costs \$2637.50) Overall Budget Period is: 8/23/2021 - 8/22/2024

5. Principal Investigator, “A Multicenter Phase 3 Trial of Biotherapy using Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU).” Total budget amount: \$268,244.24 (\$214,595.39 direct costs and indirect costs \$53,648.85) Overall Budget Period is: 3/19/2020 - 3/18/22

6. Principal Investigator, “Evaluation of Micro Water Jet Technology and the Progression of Wound Healing: A Prospective Cohort Evaluating the Efficacy of Micro Water Jet Technology in the debridement and healing of Chronic Lower Extremity Ulcers” Medaxis LLC. Total budget amount: \$37,925.00 (direct costs: \$27,089, indirect costs \$10,836.00). Overall Budget Period: 12/17/19 - 12/16/21

7. Principal Investigator, “Promoting Compliance in the utilization of Offloading Footwear in Patients with Diabetic Foot Ulcers” Smith & Nephew Inc. Total budget amount: 69,312.50 (direct costs: \$56,062.50, indirect costs \$13,250.00). Overall Budget Period: 10/1/19-09/30/21

8. Principal Investigator, “Effect of Vitamin C on Skin Flora in Patients with Diabetic Foot Ulcers vs. Controls.” APMSA. Total budget amount: \$1500.00. Overall Budget Period: 08/01/19 – 07/31/20.

9. Principal investigator, “A Phase II, Prospective, Randomized, Double-Blind, Multi-center, Placebo-Controlled Trial of DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis.” ReVance Therapeutics. Overall Anticipated Amount: \$ 235,258.75. Overall Budget Period: 3/05/19 - 3/04/21

10. Principal Investigator, “A Multi-center, Open Label Phase 2 Pilot Trial of Subjects with Non-Healing Venous Leg Ulcers Treated with Standard Care plus Cryopreserved Human Umbilical Cord (TTAX01).” TissueTech. Overall Anticipated Amount is: \$ 97,258.75. Overall Budget Period: 2/8/19 - 2/7/21

11. Principal Investigator, “Comparison of Skin Flora in Patients with Diabetic Foot Ulcers vs. Controls.” APMSA. Total budget amount: \$1500.00. Overall Budget Period: 03/01/19 – 09/30/19.

12. Principal Investigator, “A Multiple-Dose, Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Dysport For the Treatment of Pain Associated with Hallux Abducto Valgus.” Medpace Clinical Research LLC. Total budget amount: \$126,995.00. Overall Budget Period: 9/01/18 - 8/31/20

13. Principal Investigator, “A Non-interventional Safety Study Providing 12-Month Follow-up from First Exposure to TTAX01 in Subjects with Complex Non-healing Diabetic Foot Ulcers.” TissueTech Ltd. (Private Industry) Total budget amount: \$19,956.25. Overall budget period 05/01/2018-04/30/2020

14. Principal Investigator, “A Multicenter, Open Label Phase 2 Pilot Trial of Subjects with Complex Non-healing Diabetic Foot Ulcers Treated with Standard Care plus Cryopreserved

Umbilical Cord Allograft (TTAX01).” TissueTech Ltd., Total budget amount: \$56,043.75 (\$46,605 direct, \$9348.75 indirect) Overall budget period: 10/03/17-10/02/19

15. Co-Principal Investigator, “Biomarkers of Wound Healing in Chronic Diabetic Patients.” Rosalind Franklin University – DePaul University Collaborative Research Grant, Anticipated project period: 04/01/2017 to 06/30/2018. Budget: \$93,590

16. Principal Investigator, “A Multi-center, Randomized, Controlled, Trial of non-healing diabetic foot ulcers (DFU) treated with standard of care with or without cryopreserved Umbilical Cord Allograft (NEOX CORD 1KTM)”, Amniox, Anticipated project period: 3/9/2016-2/28/2018, Budget: \$175,202.50.

17. Principal Investigator, “Summer Research Fellowship Program for Podiatric Medical Students” NIH T35 Grant 2T35DK074390-06, \$288,000, 2014-2019

- Other disclosures: None

When you have nothing to disclose, please state here:

Signature and date

A handwritten signature in black ink, appearing to be a stylized 'A' or similar character, written over a horizontal line.

April 8, 2023

